@article{ART001530431,
author={유한석 and 허선화 and 김효진 and 이종석 and 전상훈 and 정진행},
title={ERCC1 Predicts a Poorer Platinum-based Chemotherapy Outcome but a Better Outcome for Uracil-Tegafur in the Resected Stage I-II NSCLC},
journal={Journal of Pathology and Translational Medicine},
issn={2383-7837},
year={2011},
volume={45},
number={1},
pages={45-52}
}

TY - JOUR
AU - 유한석
AU - 허선화
AU - 김효진
AU - 이종석
AU - 전상훈
AU - 정진행
TI - ERCC1 Predicts a Poorer Platinum-based Chemotherapy Outcome but a Better Outcome for Uracil-Tegafur in the Resected Stage I-II NSCLC
T2 - Journal of Pathology and Translational Medicine
JO - Journal of Pathology and Translational Medicine
PY - 2011
VL - 45
IS - 1
PB - 대한병리학회
SP - 45
EP - 52
SN - 2383-7837
AB - Background: The role of excision repair cross-complementation group 1 (ERCC1) has been controversial in non-small cell lung cancer (NSCLC) patients who received adjuvant chemotherapy with a platinum agent. We investigated ERCC1 expression in stage I-II NSCLC to clarify its significance for adjuvant chemotherapy. Methods: The ERCC1 expression profile was evaluated by immunohistochemistry and compared according to adjuvant chemotherapeutic agents in 146 patients who underwent surgical resection for stage I-II NSCLC. The patients were divided into 3 groups; adjuvant chemotherapy with a platinum based agent (18.5%, 27/146); adjuvant chemotherapy with uracil-tegafur (UFT) (40.4%, 59/146); surgery-alone (41.1%, 60/146). Results: Nuclear ERCC1 expression was detected in 71.9% (105/146) of NSCLC and was significantly associated with a shortened survival period in the group 1 patients who received the platinum based regimen after surgery. The group 2 patients who received UFT showed the longest survival period, followed by the surgery-alone group (overall survival, p=0.049; disease-free survival [DFS], p<0.001). Conclusions: These results suggest that stage I-II NSCLC patients with ERCC1 expression experience a shorter DFS period with adjuvant chemotherapy with a platinum based regimen and may benefit from adjuvant chemotherapy with UFT, instead of platinum after surgery.
KW - Carcinoma, non-small-cell lung; ERCC1 protein, human; Chemotherapy, adjuvant
DO -
UR -
ER -

유한석, 허선화, 김효진, 이종석, 전상훈 and 정진행. 2011, "ERCC1 Predicts a Poorer Platinum-based Chemotherapy Outcome but a Better Outcome for Uracil-Tegafur in the Resected Stage I-II NSCLC", Journal of Pathology and Translational Medicine, vol.45, no.1 pp.45-52.

유한석, 허선화, 김효진, 이종석, 전상훈, 정진행 "ERCC1 Predicts a Poorer Platinum-based Chemotherapy Outcome but a Better Outcome for Uracil-Tegafur in the Resected Stage I-II NSCLC" Journal of Pathology and Translational Medicine 45.1 pp.45-52 (2011) : 45.

유한석, 허선화, 김효진, 이종석, 전상훈, 정진행. ERCC1 Predicts a Poorer Platinum-based Chemotherapy Outcome but a Better Outcome for Uracil-Tegafur in the Resected Stage I-II NSCLC. 2011; 45(1), 45-52.

유한석, 허선화, 김효진, 이종석, 전상훈 and 정진행. "ERCC1 Predicts a Poorer Platinum-based Chemotherapy Outcome but a Better Outcome for Uracil-Tegafur in the Resected Stage I-II NSCLC" Journal of Pathology and Translational Medicine 45, no.1 (2011) : 45-52.

유한석; 허선화; 김효진; 이종석; 전상훈; 정진행. ERCC1 Predicts a Poorer Platinum-based Chemotherapy Outcome but a Better Outcome for Uracil-Tegafur in the Resected Stage I-II NSCLC. Journal of Pathology and Translational Medicine, 45(1), 45-52.

유한석; 허선화; 김효진; 이종석; 전상훈; 정진행. ERCC1 Predicts a Poorer Platinum-based Chemotherapy Outcome but a Better Outcome for Uracil-Tegafur in the Resected Stage I-II NSCLC. Journal of Pathology and Translational Medicine. 2011; 45(1) 45-52.

유한석, 허선화, 김효진, 이종석, 전상훈, 정진행. ERCC1 Predicts a Poorer Platinum-based Chemotherapy Outcome but a Better Outcome for Uracil-Tegafur in the Resected Stage I-II NSCLC. 2011; 45(1), 45-52.

유한석, 허선화, 김효진, 이종석, 전상훈 and 정진행. "ERCC1 Predicts a Poorer Platinum-based Chemotherapy Outcome but a Better Outcome for Uracil-Tegafur in the Resected Stage I-II NSCLC" Journal of Pathology and Translational Medicine 45, no.1 (2011) : 45-52.